CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 31 enrolled
Drug / intervention
eltrombopag olaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02071901
NCT02071901Phase 2Unknown
CompareCT.gov

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy

Case Comprehensive Cancer Center·interventional·Posted Feb 26, 2014·Updated Dec 1, 2021

In Brief

A Phase 2 clinical trial evaluating eltrombopag olamine for Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome and 18 related conditions. Targeting 31 participants across 1 site.

Detailed Summary

This phase II trial studies how well eltrombopag olamine works in improving the recovery of platelet counts in older patients with Acute Myeloid Leukemia (AML) undergoing induction (the first treatment given for a disease) chemotherapy. Platelet counts recover more slowly in older patients, leading to risk of complications and the delay of post-remission therapy. Eltrombopag olamine may cause the body to make platelets after chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2UnknownOverdue
2014201520162017201820192020202120222023202420252026
First PostedFeb 26, 2014
Enrollment StartAug 14, 2014
Primary CompletionOct 20, 2018
Study CompletionSep 26, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 12.3 years ago

Interventions

eltrombopag olaminedrug

Given PO